Clinical trial
A Single Center, Single Arm Phase I Clinical Study of GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors
NCT06077903 is registered in ClinicalTrials.gov with Grit Biotechnology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Single Center, Single Arm Phase I Clinical Study of GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors
- Lead sponsor
- Grit Biotechnology
- Phase
- Phase 1
- Overall status
- Terminated
- Start date
- July 5, 2021
- Completion date
- December 30, 2025
- Enrollment
- 10 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
adult